DK0646009T3 - Anvendelse af guanosin til fremstilling af lægemidler beregnet til behandling af cerebrale funktionsdefekter - Google Patents

Anvendelse af guanosin til fremstilling af lægemidler beregnet til behandling af cerebrale funktionsdefekter

Info

Publication number: DK0646009T3
Authority: DK; Denmark
Prior art keywords: guanosine; manufacture; malfunctions; drugs intended; treat cerebral
Prior art date: 1992-06-24

Application number

DK93913178T

Other languages

Danish (da)

English (en)

Inventor

Marie A Peeters

Jer Me Lejeune

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-24

Filing date

1993-06-23

Publication date

1999-05-17

1993-06-23 Application filed by Pf Medicament filed Critical Pf Medicament

1999-05-17 Application granted granted Critical

1999-05-17 Publication of DK0646009T3 publication Critical patent/DK0646009T3/da

Links

NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 title abstract 4
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 title abstract 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
229940029575 guanosine Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
230000002490 cerebral effect Effects 0.000 title 1
230000007257 malfunction Effects 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000011580 syndromic disease Diseases 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
208000001914 Fragile X syndrome Diseases 0.000 abstract 1
201000006347 Intellectual Disability Diseases 0.000 abstract 1
208000036626 Mental retardation Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000003542 behavioural effect Effects 0.000 abstract 1
230000005978 brain dysfunction Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000002759 chromosomal effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000035874 hyperreactivity Effects 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK93913178T 1992-06-24 1993-06-23 Anvendelse af guanosin til fremstilling af lægemidler beregnet til behandling af cerebrale funktionsdefekter DK0646009T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9207721A FR2692784B1 (fr)	1992-06-24	1992-06-24	Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
PCT/FR1993/000625 WO1994000132A1 (fr)	1992-06-24	1993-06-23	Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux

Publications (1)

Publication Number	Publication Date
DK0646009T3 true DK0646009T3 (da)	1999-05-17

Family

ID=9431118

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93913178T DK0646009T3 (da)	1992-06-24	1993-06-23	Anvendelse af guanosin til fremstilling af lægemidler beregnet til behandling af cerebrale funktionsdefekter

Country Status (7)

Country	Link
EP (1)	EP0646009B1 (de)
AT (1)	ATE169500T1 (de)
AU (1)	AU4333893A (de)
DE (1)	DE69320349D1 (de)
DK (1)	DK0646009T3 (de)
FR (1)	FR2692784B1 (de)
WO (1)	WO1994000132A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ380296A3 (cs) *	1994-07-25	1998-01-14	Alvin J. Glasky	Léčivo pro dlouhodobou modifikaci savčí neurální aktivity, léčení neurologických chorob, indukci dlouhodobých změn membránového potenciálu neuronů a jiné účely
US6440455B1 (en)	1997-09-02	2002-08-27	Children's Medical Center Corporation	Methods for modulating the axonal outgrowth of central nervous system neurons
WO2000006171A1 (en) *	1998-07-31	2000-02-10	Hme Enterprises, Llc	Antioxidant composition and method of treating diseases using same
US20020045580A1 (en) *	1999-11-24	2002-04-18	Sacks Meir S.	Compositions for raising uric acid levels and methods of using same
US6365593B2 (en)	2000-04-12	2002-04-02	Repligen Corporation	Methylxanthines in the diagnosis and treatment of autistic disorder
US7172871B1 (en)	2000-09-07	2007-02-06	Children's Medical Center Corporation	Methods and compositions for modulating axonal outgrowth of central nervous system neurons
CA2497437A1 (en) *	2002-09-03	2004-03-18	Neurological Technologies Inc.	Purine nucleosides as anti-apoptotic agents
US8912144B2 (en)	2003-12-16	2014-12-16	Children's Medical Center Corporation	Method for treating stroke via administration of NEP1-40 and inosine
WO2010101587A1 (en) *	2009-03-04	2010-09-10	Children's Medical Center Corporation	Use of hypoxanthine for promotion of neuronal outgrowth
JP2015030673A (ja) *	2013-07-31	2015-02-16	奥野製薬工業株式会社	アミロイドベータペプチド阻害剤
CN111973615A (zh) *	2019-05-22	2020-11-24	华东理工大学	一种治疗躁狂型精神障碍及精神分裂症的药物
JP7646137B2 (ja) *	2022-01-07	2025-03-17	株式会社マルハチ村松	精神神経疾患を予防または改善するための鰹由来抽出物を含む機能性食品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR5084E (fr) *	1905-06-23	1905-12-11	Etienne Auguste Marie Faure	Système d'aération continue ou alternative
JPS41137Y1 (de) *	1964-04-23	1966-01-07
JPS41136Y1 (de) *	1965-04-09	1966-01-07
FR2437834A1 (fr) *	1978-10-04	1980-04-30	Lejeune Jerome	Compositions pharmaceutiques a base de l-serine ou de glycine
JPS61277619A (ja) *	1985-06-04	1986-12-08	Otsuka Pharmaceut Factory Inc	肝疾患治療剤
DE3701497A1 (de) *	1987-01-20	1988-07-28	Frankhof Wolfgang	Arzneimittel, enthaltend lokalanaesthetika und nukleoside sowie dessen verwendung zur behandlung von muskelverletzungen
DE68919169T2 (de) *	1988-08-16	1995-04-20	Nippon Shinyaku Co Ltd	Nucleotid-Derivate.
FR2665636B1 (fr) *	1990-08-10	1994-10-07	Adir	Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.

1992
- 1992-06-24 FR FR9207721A patent/FR2692784B1/fr not_active Expired - Fee Related
1993
- 1993-06-23 AT AT93913178T patent/ATE169500T1/de not_active IP Right Cessation
- 1993-06-23 DE DE69320349T patent/DE69320349D1/de not_active Expired - Lifetime
- 1993-06-23 EP EP93913178A patent/EP0646009B1/de not_active Expired - Lifetime
- 1993-06-23 AU AU43338/93A patent/AU4333893A/en not_active Abandoned
- 1993-06-23 DK DK93913178T patent/DK0646009T3/da active
- 1993-06-23 WO PCT/FR1993/000625 patent/WO1994000132A1/fr not_active Ceased

Also Published As

Publication number	Publication date
ATE169500T1 (de)	1998-08-15
FR2692784B1 (fr)	1995-06-30
EP0646009A1 (de)	1995-04-05
FR2692784A1 (fr)	1993-12-31
EP0646009B1 (de)	1998-08-12
AU4333893A (en)	1994-01-24
WO1994000132A1 (fr)	1994-01-06
DE69320349D1 (de)	1998-09-17

Similar Documents

Publication	Publication Date	Title
GR3019450T3 (en)	1996-06-30	Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system
DK0713701T3 (da)	2000-04-03	2-Brommelatonin til behandling af søvnforstyrrelser
EE200200274A (et)	2003-06-16	Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
KR100521829B1 (en)	2005-10-17	Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
DK1303495T3 (da)	2010-09-20	Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE377592T1 (de)	2007-11-15	Neurotropische substituierte pyrimidine
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
NL300406I1 (nl)	2009-11-02	Gesubstitueerde dihydrodibenzo (d,f)azepinen, werkwijze ter bereiding ervan, hun toepassing bij het behandelen van enkele verstoringen van het centraal zenuwsysteem, en farmaceutische samenstellingen die ze bevatten
DE60318860D1 (de)	2008-03-13	Chinucledin - derivate und deren verwendung
ATE97809T1 (de)	1993-12-15	Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe und wirksam in der therapie organisch mentaler stoerungen sowie die entsprechenden arzneimittel.
ATE412415T1 (de)	2008-11-15	Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
ITMI930699A1 (it)	1994-10-08	Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
NO20041166L (no)	2004-03-19	Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
AR028705A1 (es)	2003-05-21	Bis-arilsulfonas
AU4333893A (en)	1994-01-24	Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction
FI101377B1 (fi)	1998-06-15	Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi
GR3019774T3 (en)	1996-07-31	Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
EP0383171A3 (de)	1991-07-24	2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
FI954614A0 (fi)	1995-09-28	Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
ATE256126T1 (de)	2003-12-15	5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
ES2144857T3 (es)	2000-06-16	Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
HK142093A (en)	1994-01-07	Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it
DE68901172D1 (de)	1992-05-14	(-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DK0538690T3 (da)	1995-03-06	Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
SE8703308L (sv)	1988-02-28	Terapeutiskt medel for behandling av sjukdomar forbundna med cerebral ischemi